First-line use of CDK4/6 inhibitors does not improve most outcomes when compared with second-line use in HR+, HER2- advanced breast cancer, phase 3 data suggest.
Combination treatment with dabrafenib, trametinib, and navitoclax has demonstrated activity in a phase 2 trial of patients with BRAFV600-mutant metastatic melanoma.
Zorifertinib improves PFS when compared to gefitinib or erlotinib as first-line treatment for EGFR-mutant NSCLC with CNS metastases, a phase 3 trial suggests.
Adding toripalimab to nab-paclitaxel improves progression-free survival in PD-L1+ metastatic/recurrent triple-negative breast cancer, a phase 3 trial suggests.
Trastuzumab deruxtecan elicits responses in patients with HER2-positive metastatic colorectal cancer, a phase 2 study suggests.
Neoadjuvant chemotherapy does not improve survival outcomes vs upfront surgery in patients with locally advanced colon cancer, a phase 3 trial suggests.
Updated data support the use of pembrolizumab in combination with chemotherapy as first-line standard care for patients with persistent, recurrent, or metastatic cervical cancer.
In the phase 3 PROSPECT trial, patients with locally advanced rectal cancer had similar outcomes if they received pelvic chemoradiation or if they received FOLFOX with chemoradiation added only in select cases.
Adding dostarlimab to treatment with carboplatin and paclitaxel improves progression-free survival in advanced or recurrent endometrial cancer, the phase 3 RUBY trial suggests.
Treatment with tucatinib and trastuzumab elicits responses in previously treated, HER2-positive metastatic biliary tract cancer.
